Treatment of type 2 diabetes mellitus oral Chinese patent medicine literature metrology analysis

2012 ◽  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Chinese Patent Medicine ◽  
Literature Metrology ◽  
Chinese Patent ◽  
Patent Medicine

scholarly journals Metabolomics-Based Clinical Efficacy and Effect on the Endogenous Metabolites of Tangzhiqing Tablet, a Chinese Patent Medicine for Type 2 Diabetes Mellitus with Hypertriglyceridemia

2018 ◽  
Vol 2018 ◽  
pp. 1-11 ◽  
Author(s):  
Jia Liu ◽  
Ziqiang Li ◽  
Hua Liu ◽  
Xianhua Wang ◽  
Chunxiao Lv ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Healthy Volunteers ◽  
Clinical Indication ◽  
Chinese Patent Medicine ◽  
Significant Difference ◽  
Chinese Patent ◽  
Patent Medicine

Tangzhiqing tablet (TZQ) is derived from Tangzhiqing formula, which has been used to regulate glucose and lipid metabolism in China for hundreds of years. However, as a new Chinese patent medicine, its clinical indication is not clear. To explore the clinical indication and effect on the patients with type 2 diabetes mellitus (T2DM), a pilot clinical trial and metabolomics study were carried out. In the clinical study, T2DM patients were divided into three groups and treated with TZQ, placebo, or acarbose for 12 weeks, respectively. The metabolomic study based on UPLC Q-TOF MS was performed including patients with hypertriglyceridemia in TZQ and placebo groups and healthy volunteers. The clinical results showed that TZQ could reduce glycosylated hemoglobin (HbA1c) and fasting insulin. For patients with hypertriglyceridemia in TZQ group, the levels of HbA1c all decreased and were correlated with the baseline level of triglyceride. Metabonomics data showed a significant difference between patients and healthy volunteers, and 17 biomarkers were identified. After 12-week treatment with TZQ, 11 biomarkers decreased significantly (p<0.05), suggesting that TZQ could improve the metabolomic abnormalities in these participants. In conclusion, the clinical indication of TZQ was T2DM with hypertriglyceridemia, and its target was related to glycerophospholipid metabolism.

scholarly journals Efficacy and Safety of the Chinese Patent Medicine Yuquan Pill on Type 2 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 2021 ◽  
pp. 1-14
Author(s):  
Sihan Peng ◽  
Ziyan Xie ◽  
Xiyu Zhang ◽  
Chunguang Xie ◽  
Jian Kang ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Conventional Treatment ◽  
Efficacy And Safety ◽  
Chinese Patent Medicine ◽  
Chinese Patent ◽  
Treatment Of Diabetes ◽  
Patent Medicine

Background. Yuquan Pill (YQP), a Chinese patent medicine for the treatment of diabetes, is widely used in the treatment of diabetes and its complications in China. However, the efficacy of YQP on type 2 diabetes mellitus (T2DM) has not been completely assessed. The aim of this study is to evaluate the efficacy and safety of YQP in the treatment of T2DM. Materials and Methods. We systematically searched 9 databases for specific keywords from inception to Oct 2021. We included randomized controlled trials (RCTs) involving YQP in the treatment of T2DM without language limitation. The study conformed to the Cochrane Handbook and Review Manager software was used for data analysis. The weighted mean differences (WMDs) and 95% confidence intervals (CIs) were used to measure treatment effects. Results. The final analysis included 10 publications. Analysis showed that the combination of YQP and conventional treatment was more effective than conventional treatment alone with regard to the levels of fasting blood glucose (WMD = −0.83; 95% CI [−1.01,−0.66]; p < 0.00001 ), two-hour postprandial glucose (WMD = −1.40; 95% CI [−1.49,−1.31]; p < 0.00001 ), glycosylated hemoglobin (WMD = −0.87; 95% CI [−1.26, −0.49]; p < 0.00001 ), total cholesterol (WMD = −0.50; 95% CI [−0.61, −0.39]; p < 0.00001 ), c-reactive protein (WMD = −0.58; 95%CI [−0.88, −0.28]; p = 0.0002 ), and overall effective rate (RR = 1.21; 95% CI [1.12, 1.31]; p < 0.00001 ). Conclusion. Evidence suggested that YQP might improve glucose and lipid metabolism and inflammation in patients with T2DM. Serious adverse events were not reported. The quality of the evidence analyzed was low and therefore our results should be interpreted with caution. More high-quality RCTs are now needed to verify these findings.

Abstract #1214: Decreasing Hypoglycemia Without Compromising Efficacy in an Aging Type 2 Diabetes Mellitus (T2Dm) Population

2015 ◽  
Vol 21 ◽  
pp. 280-281
Author(s):  
Medha Munshi ◽  
Jasvinder Gill ◽  
Jason Chao ◽  
Elena Nikonova ◽  
Andreas Stuhr ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus
Sign in / Sign up

Export Citation Format

Share Document